{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:17:37Z","timestamp":1792621057247,"version":"4.5.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor immune escape, a defining hallmark of malignant tumors, enables cancer cells to thrive within the host by evading detection and attack by the immune system. While immune checkpoint inhibitors, such as PD-1\/PD-L1 antibodies, have delivered significant clinical advances, their effectiveness is tempered by modest response rates and a growing challenge of drug resistance. In this study, we aimed to explore the development process and trend of tumor immune escape, analyze the current hot spots, and predict the future research directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A bibliometric analysis was conducted in this study to retrieve and analyze 1839 publications from January 1, 2009 to February 14, 2025 related to tumor immune escape. Literature was obtained from Web of Science Core Collection (WoSCC) and data visualization and trend analysis were performed using VOSviewer, CiteSpace, Bibliometrix software package.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The bibliometric analysis indicates that research on tumor immune escape has primarily focused on China, the United States, and European countries. China ranks first in research output and impact, with notable contributions from institutions like the Sun Yat-sen University System and the University of Texas System. The journal with the most publications is Frontiers in Immunology, while the most cited article globally is Jiang P\u2019s 2018 publication in Nature Medicine, titled \u201cSignatures of T cell dysfunction and exclusion predict cancer immunotherapy response.\u201d Keyword co-occurrence and burst analysis indicate that the field has undergone a thematic evolution. Early research centered around classical immune checkpoint molecules and T cell exhaustion, while more recent trends have shifted toward the tumor microenvironment (TME), multi-target combination immunotherapies, and mechanisms of immune evasion involving metabolic reprogramming and the microbiome. The integration of artificial intelligence (AI) and machine learning (ML) in immunotherapy prediction and biomarker discovery has also gained momentum, highlighting a growing cross-disciplinary approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This bibliometric study provides a comprehensive overview of the intellectual landscape, research hotspots, and developmental trajectory of tumor immune escape research over the past 14 years. By mapping influential nation, authors, core journals, reference, and keyword bursts, this work not only summarizes major contributions in the field but also helps researchers better understand its evolution and emerging directions. Based on the observed patterns, we propose three key areas that warrant further exploration: (1) advancing interdisciplinary research at the intersection of the microbiome, metabolism, and immune regulation; (2) integrating artificial intelligence and multi-omics data to enhance predictive modeling and therapeutic precision; and (3) combining multi-modal therapeutic strategies to overcome immune escape more effectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1604216","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:25:34Z","timestamp":1756358734000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Trends and hotspots in research related to tumor immune escape: bibliometric analysis and future perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Houcheng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2240-6","article-title":"Overview and countermeasures of cancer burden in China","volume":"66","author":"Wang","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"189269","DOI":"10.1016\/j.bbcan.2025.189269","article-title":"Neuromedin U in the tumor microenvironment - Possible actions in tumor progression","volume":"1880","author":"Przygodzka","year":"2025","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"217466","DOI":"10.1016\/j.canlet.2025.217466","article-title":"Metabolic reprogramming of neutrophils in the tumor microenvironment: Emerging therapeutic targets","volume":"612","author":"Huang","year":"2025","journal-title":"Cancer letters"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417357","article-title":"Effect of extracellular vesicles derived from tumor cells on immune evasion","volume":"12","author":"Liu","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semcancer.2025.01.008","article-title":"Drivers of centrosome abnormalities: Senescence progression and tumor immune escape","volume":"110","author":"Jiang","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.12.001","article-title":"Pivotal role of PD-1\/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals","volume":"86","author":"Lee","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2025.02.005","article-title":"Inflammation and tumor immune escape in response to DNA damage","volume":"110","author":"Nihira","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"115234","DOI":"10.1016\/j.celrep.2025.115234","article-title":"Emerging insights into the impact of systemic metabolic changes on tumor-immune interactions","volume":"44","author":"Cote","year":"2025","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/S40037-021-00695-4","article-title":"Bibliometrics: Methods for studying academic publishing","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect Med education"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460533","article-title":"Antiangiogenic therapy exerts antitumor effects by altering the tumor microenvironment: bibliometric analysis","volume":"15","author":"Kang","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519498","article-title":"A bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"112238","DOI":"10.1016\/j.biopha.2021.112238","article-title":"An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1\/PD-L1 drugs to treat cancers","volume":"143","author":"Liu","year":"2021","journal-title":"Biomed pharmacother = Biomed pharmacotherapie"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1616626","article-title":"Variations in databases used to assess academic output and citation impact","volume":"376","author":"Plana","year":"2017","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Sci (New York NY)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041396","article-title":"Divide and conquer-targeted therapy for triple-negative breast cancer","volume":"26","author":"Nedeljkovi\u0107","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101335","DOI":"10.1016\/j.mam.2024.101335","article-title":"The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy","volume":"101","author":"Xie","year":"2025","journal-title":"Mol aspects Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12943-025-02258-1","article-title":"Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment","volume":"24","author":"Wan","year":"2025","journal-title":"Mol cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183215","article-title":"Evidence of the link between stroma remodeling and prostate cancer prognosis","volume":"16","author":"Vecchiotti","year":"2024","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-025-03318-6","article-title":"Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade","volume":"44","author":"Li","year":"2025","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-025-02270-5","article-title":"Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines","volume":"24","author":"Maksymova","year":"2025","journal-title":"Mol cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30073-5","article-title":"Cancer registration in China and its role in cancer prevention and control","volume":"21","author":"Wei","year":"2020","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e996","DOI":"10.1016\/S2468-2667(23)00186-X","article-title":"Cancer screening in China: a steep road from evidence to implementation","volume":"8","author":"Xia","year":"2023","journal-title":"Lancet Public Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: an analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun (London England)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0387","article-title":"Cancer burden in China: trends, risk factors and prevention","volume":"17","author":"Sun","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac104","article-title":"The development of global cancer research at the United States national cancer institute","volume":"114","author":"Parascandola","year":"2022","journal-title":"J Natl Cancer Institute"},{"key":"B43","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00634-4","article-title":"Cancer control collaborations between China and African countries","volume":"25","author":"Ngoma","year":"2024","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.03.008","article-title":"Glucose metabolism of TAMs in tumor chemoresistance and metastasis","volume":"33","author":"Liu","year":"2023","journal-title":"Trends Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12330","article-title":"Antibody variable region engineering for improving cancer immunotherapy","volume":"42","author":"Lou","year":"2022","journal-title":"Cancer Commun (London England)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc Natl Acad Sci U States A"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death differentiation"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310866121","article-title":"Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function","volume":"121","author":"Silberstein","year":"2024","journal-title":"Proc Natl Acad Sci U States A"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01238-7","article-title":"LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition","volume":"23","author":"Ming","year":"2022","journal-title":"Nat Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"New Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/pharmrev.122.000788","article-title":"Emergence of extracellular vesicles as \u201cLiquid biopsy\u201d for neurological disorders: boom or bust","volume":"76","author":"Kumar","year":"2024","journal-title":"Pharmacol Rev"},{"key":"B58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-019-0982-6","article-title":"Exosome-orchestrated hypoxic tumor microenvironment","volume":"18","author":"Meng","year":"2019","journal-title":"Mol cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-018-0869-y","article-title":"Role of hypoxia-induced exosomes in tumor biology","volume":"17","author":"Shao","year":"2018","journal-title":"Mol cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"189275","DOI":"10.1016\/j.bbcan.2025.189275","article-title":"Extracellular vesicles and the tumor microenvironment","volume":"1880","author":"Bel\u00e9nyesi","year":"2025","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.001","article-title":"NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps","volume":"41","author":"Adrover","year":"2023","journal-title":"Cancer Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/pcmr.12818","article-title":"Evidence and impact of neutrophil extracellular traps in Malignant melanoma","volume":"33","author":"Schedel","year":"2020","journal-title":"Pigment Cell melanoma Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008662","article-title":"CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs","volume":"12","author":"Xiong","year":"2024","journal-title":"J immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2024.01.013","article-title":"Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment","volume":"42","author":"He","year":"2024","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"115605","DOI":"10.1016\/j.ejca.2025.115605","article-title":"Approaches to overcome the current treatment plateau in immunotherapy","volume":"226","author":"Di Giacomo","year":"2025","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2025.06.008","article-title":"Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC","volume":"12","author":"Ju","year":"2025","journal-title":"Trends Endocrinol metabolism: TEM"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214278119","article-title":"Tumor-targeted delivery of a STING agonist improvescancer immunotherapy","volume":"119","author":"Wu","year":"2022","journal-title":"Proc Natl Acad Sci U States A"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumor efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet (London England)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"0764","DOI":"10.34133\/research.0764","article-title":"Daurisoline modulates the TBK1-dependent type I interferon pathway to boost anti-tumor immunity via targeting of LRP1","volume":"8","author":"Tang","year":"2025","journal-title":"Res (Washington DC)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012269","article-title":"Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS\/STING axis in osteosarcoma lung metastasis","volume":"13","author":"Liu","year":"2025","journal-title":"J immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1299977","article-title":"Gut microbiome: decision-makers in the microenvironment of colorectal cancer","volume":"13","author":"Han","year":"2023","journal-title":"Front Cell infection Microbiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215317","article-title":"Gut microbiota and tumor immune escape: A new perspective for improving tumor immunotherapy","volume":"14","author":"He","year":"2022","journal-title":"Cancers"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0617","article-title":"Microenvironmental metabolism regulates antitumor immunity","volume":"79","author":"Ngwa","year":"2019","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"13810","DOI":"10.1038\/s41598-023-41107-3","article-title":"A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers","volume":"13","author":"Liu","year":"2023","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2388801","DOI":"10.1080\/19490976.2024.2388801","article-title":"Porphyromonas gingivalis fuels colorectal cancer through CHI3L1-mediated iNKT cell-driven immune evasion","volume":"16","author":"D\u00edaz-Basabe","year":"2024","journal-title":"Gut Microbes"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2580","article-title":"Intratumoral fusobacterium nucleatum recruits tumor-associated neutrophils to promote gastric cancer progression and immune evasion","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut microbiota in cancer immune response and immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.12.023","article-title":"Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver","volume":"80","author":"Andrews","year":"2024","journal-title":"J hepatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05672-3","article-title":"Single-cell spatial landscapes of the lung tumor immune microenvironment","volume":"614","author":"Sorin","year":"2023","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/biology14050479","article-title":"FPCAM: A weighted dictionary-driven model for single-cell annotation in pulmonary fibrosis","volume":"14","author":"Liu","year":"2025","journal-title":"Biology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01678-9","article-title":"Decoding the tumor microenvironment with spatial technologies","volume":"24","author":"Walsh","year":"2023","journal-title":"Nat Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0090","article-title":"Artificial intelligence in cancer research and precision medicine","volume":"11","author":"Bhinder","year":"2021","journal-title":"Cancer discov"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1523902","article-title":"Opportunities and challenges with artificial intelligence in allergy and immunology: a bibliometric study","volume":"12","author":"Xiao","year":"2025","journal-title":"Front Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12967-025-06733-7","article-title":"Identification of matrix stiffness-related molecular subtypes in HCC via integrating multi-omics analysis and machine learning algorithms","volume":"23","author":"Li","year":"2025","journal-title":"J Trans Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177310","article-title":"The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV","volume":"135","author":"Desai","year":"2025","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1038\/s41467-025-57541-y","article-title":"Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s41065-025-00487-4","article-title":"WMRCA\u2009+\u2009: a weighted majority rule-based clustering method for cancer subtype prediction using metabolic gene sets","volume":"162","author":"Liu","year":"2025","journal-title":"Hereditas"},{"key":"B90","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13046-025-03473-w","article-title":"Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma","volume":"44","author":"Shifman","year":"2025","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B91","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13046-025-03452-1","article-title":"The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution","volume":"44","author":"Wu","year":"2025","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B92","doi-asserted-by":"publisher","first-page":"217928","DOI":"10.1016\/j.canlet.2025.217928","article-title":"Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation","volume":"631","author":"Li","year":"2025","journal-title":"Cancer letters"},{"key":"B93","doi-asserted-by":"publisher","first-page":"vdae174","DOI":"10.1093\/noajnl\/vdae174","article-title":"The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review","volume":"6","author":"Schonfeld","year":"2024","journal-title":"Neuro-oncol Adv"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","article-title":"Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas","volume":"15","author":"Arrieta","year":"2024","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf157","article-title":"CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma","author":"Luo","year":"2025","journal-title":"Neuro-oncology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"102183","DOI":"10.1016\/j.xcrm.2025.102183","article-title":"BRAF\/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF(V600E)-mutant glioma","volume":"6","author":"Xing","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:25:36Z","timestamp":1756358736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2025.1604216"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1604216","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"article-number":"1604216"}}